Search
Myxopyronin B
go.drugbank.com/drugs/DB08226ExperimentalCategories: DNA-Directed RNA Polymerases, antagonists & inhibitorsMelperone
go.drugbank.com/drugs/DB09224InvestigationalMelperone has been used for a span of greater than 30 years in the European Union [L1316]. … Recently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316].
Categories: Dopamine D2 Receptor AntagonistsProducts: MELPERON 1A PHARMA 50MG, MELPERON 1A PHARM 25MG/5MLAAV8-RK-RetGC
go.drugbank.com/drugs/DB32389ExperimentalAAV8-RK-RetGC is an adeno-associated virus (AAV) viral vector platform with a serotype 8 capsid with a complementary DNA (cDNA) of the human GUCY2D gene encoding RetGC.
ALMB-0166
go.drugbank.com/drugs/DB17937InvestigationalALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of acute spinal cord injury. It was granted FDA orphan designation in November 2018.[L47067]
XP12B
go.drugbank.com/drugs/DB04928InvestigationalIt was granted Fast Track status for this indication by the FDA in November 2004.
Milnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalNevertheless, milnacipran demonstrates a somewhat unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and noradrenaline, with a somewhat increased preference … Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment
Dimethylthiambutene
go.drugbank.com/drugs/DB01444ExperimentalIllicitDimethylthiambutene (N,N-Dimethyl-1-methyl-3,3-di-2-thienylallylamine, Dimethibutin, Ohton) is an opioid analgesic drug.
Synonyms: 3-dimethylamino-1,1-di-(2'-thienyl)-1-butene, N,N,1-trimethyl-3,3-di-2-thienylallylamineLondamocitinib
go.drugbank.com/drugs/DB19190InvestigationalLondamocitinib is under investigation in clinical trial NCT06020014 (Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-severe Asthma Uncontrolled on Medium-high
Satralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigational[A218551] It received subsequent approvals in Switzerland and Japan,[A218551] and was approved for use by the FDA in August 2020,[L15566] becoming the 3rd treatment to receive FDA approval for NMOSD (after … Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on
Sonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigational[L56193,A275521] Sonrotoclax was rationally designed as a BH3 mimetic with a shallow and broad interaction with the P2 pocket of BCL-2, achieved through a novel 7-azaspiro[3.5]nonane linker; this binding … lines of systemic therapy, including a BTK inhibitor.